Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
innate donor lymphocyte infusion
- Development stage
- Unknown
- Lead developer
- Rigshospitalet
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Innate donor lymphocyte infusion (iDLI) is an adoptive cell therapy product consisting of donor-derived innate lymphocytes, specifically enriched for natural killer (NK) cells and γδ T cells. It is developed for administration after allogeneic hematopoietic stem cell transplantation (HSCT) to treat or prevent relapse in patients with hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The product is manufactured via an automated immunomagnetic depletion process (e.g., using the CliniMACS Prodigy system) to remove αβ T cells and CD19+ B-cells from a donor leukapheresis product. By removing αβ T cells, iDLI significantly reduces the risk of graft-versus-host disease (GVHD) while maintaining the graft-versus-leukemia (GVL) effect mediated by NK and γδ T cells through HLA-independent recognition of malignant cells.
- Other names
- innate DLITCRαβ/CD19-depleted donor lymphocyte infusioninnate effector allogeneic lymphocyte infusion
Beyond the preview
Go deeper on innate donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on innate donor lymphocyte infusion.